Edition:
India

Eiger BioPharmaceuticals Inc (EIGR.OQ)

EIGR.OQ on NASDAQ Stock Exchange Global Market

14.25USD
12:24am IST
Change (% chg)

$0.94 (+7.06%)
Prev Close
$13.31
Open
$13.19
Day's High
$14.27
Day's Low
$13.19
Volume
27,426
Avg. Vol
41,740
52-wk High
$18.00
52-wk Low
$8.20

Latest Key Developments (Source: Significant Developments)

Clinigen Partners With Eiger Biopharmaceuticals To Launch Lonafarnib Managed Access Program
Monday, 4 Mar 2019 

March 4 (Reuters) - Clinigen Group PLC ::PARTNERED WITH EIGER BIOPHARMACEUTICALS TO LAUNCH LONAFARNIB MANAGED ACCESS PROGRAM FOR PATIENTS WITH PROGERIA, PROGEROID LAMINOPATHIES.  Full Article

Eiger Announces Breakthrough Therapy Designation Granted By FDA For Lonafarnib For Treatment Of Hepatitis Delta Virus Infection
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER ANNOUNCES BREAKTHROUGH THERAPY DESIGNATION GRANTED BY FDA FOR LONAFARNIB FOR TREATMENT OF HEPATITIS DELTA VIRUS (HDV) INFECTION.  Full Article

Eiger Biopharmaceuticals Says >$100 Mln In Cash Available To Achieve Key Milestones
Wednesday, 12 Dec 2018 

Dec 11 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS INC - ON 2018 RESEARCH AND DEVELOPMENT DAY, MORE THAN $100 MILLION IN CASH AVAILABLE TO ACHIEVE KEY MILESTONES.  Full Article

Eiger Biopharma Announces FDA Acceptance Of IND Application For Progeria Treatment
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR LONAFARNIB FOR THE TREATMENT OF PROGERIA AND PROGEROID LAMINOPATHIES.EIGER BIOPHARMACEUTICALS INC - PLANS TO FILE NDA IN 2019.  Full Article

Eiger BioPharmaceuticals Announces Proposed Public Offering Of Common Stock
Tuesday, 23 Oct 2018 

Oct 22 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.EIGER BIOPHARMACEUTICALS INC - PLANS TO USE PROCEEDS TO FUND PLANNED PHASE 3 CLINICAL TRIAL OF LONAFARNIB FOR HEPATITIS DELTA VIRUS.EIGER BIOPHARMACEUTICALS INC - PLANS TO USE PROCEEDS TO FUND REGULATORY ADVANCEMENT OF LONAFARNIB RELATED TO TREATMENT OF PROGERIA.  Full Article

Eiger Announces FDA Guidance On HDV Phase 3 Study Design; Primary Endpoint Established
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER ANNOUNCES FDA GUIDANCE ON HDV PHASE 3 STUDY DESIGN: PRIMARY ENDPOINT ESTABLISHED; D-LIVR STUDY INITIATING Q4 2018.EIGER BIOPHARMACEUTICALS - RECEIVED WRITTEN GUIDANCE FROM FDA, CONFIRMING CONCURRENCE ON PIVOTAL TRIAL DESIGN, INCLUDING PRIMARY ENDPOINT FOR D-LIVR.  Full Article

Eiger Biopharmaceuticals Q4 Loss Per Share $1.11
Monday, 12 Mar 2018 

March 12 (Reuters) - Eiger Biopharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $1.11.Q4 EARNINGS PER SHARE VIEW $-1.02 -- THOMSON REUTERS I/B/E/S.‍CASH RUNWAY EXTENDS THROUGH MID-2019​.  Full Article

Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Eiger Biopharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT.EIGER BIOPHARMACEUTICALS INC - EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT.EIGER BIOPHARMACEUTICALS INC - END OF PHASE 2 MEETING SCHEDULED FOR HDV IN FEBRUARY 2018.EIGER BIOPHARMACEUTICALS INC - NO SAFETY SIGNALS ATTRIBUTED TO UBENIMEX WERE IDENTIFIED IN PRELIMINARY ANALYSIS.EIGER BIOPHARMACEUTICALS - FURTHER ANALYSIS OF DATA, INCLUDING BIOMARKERS IS ONGOING, ALTHOUGH CO TO DISCONTINUE DEVELOPMENT OF UBENIMEX IN PAH.EIGER BIOPHARMACEUTICALS INC - WILL CONTINUE TO DEVELOP UBENIMEX FOR LYMPHEDEMA BASED ON ITS DISTINCT MECHANISM OF ACTION IMPACTING LYMPHANGIOGENESIS.EIGER BIOPHARMACEUTICALS INC - EIGER IS DEVELOPING UBENIMEX FOR LYMPHEDEMA IN ULTRA STUDY.  Full Article

‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Eiger Biopharmaceuticals Inc :‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​ as of Oct 31 - SEC filing.  Full Article

Eiger Biopharmaceuticals reports Q3 loss per share $1.10
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Eiger Biopharmaceuticals Inc :Eiger Biopharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $1.10.Q3 earnings per share view $-1.28 -- Thomson Reuters I/B/E/S.Eiger Biopharmaceuticals - ‍As of Sept 30, 2017, Eiger had cash, cash equivalents and short-term marketable securities of $32.3 million.Eiger Biopharmaceuticals Inc - ‍Company estimates its cash runway now extends into mid-2019​.  Full Article